Edition:
United Kingdom

Spero Therapeutics Inc (SPRO.OQ)

SPRO.OQ on NASDAQ Stock Exchange Global Select Market

11.56USD
5:19pm GMT
Change (% chg)

$-0.07 (-0.60%)
Prev Close
$11.63
Open
$11.65
Day's High
$11.97
Day's Low
$11.51
Volume
2,452
Avg. Vol
--
52-wk High
$15.39
52-wk Low
$9.94

Latest Key Developments (Source: Significant Developments)

‍GlaxoSmithKline reports 13.3 percent stake in Spero Therapeutics
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Spero Therapeutics Inc :‍GlaxoSmithKline PLC reports a 13.3 percent stake in Spero Therapeutics Inc as of November 6 - SEC filing​.  Full Article

Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Merck & Co Inc :Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing​.  Full Article

Spero Therapeutics shares open at $13.25 in debut on the NASDAQ, about 5.4 pct below IPO price‍​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - :Spero Therapeutics Inc shares open at $13.25 on the NASDAQ versus IPO price of $14.00 per share‍​.  Full Article

Spero Therapeutics announces pricing of initial public offering
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Spero Therapeutics Inc :Spero Therapeutics Inc announces pricing of initial public offering.Spero Therapeutics Inc says priced its initial public offering of 5.5 million shares of its common stock at public offering price of $14.00 per share​.  Full Article

Spero Therapeutics ‍commenced an IPO of 5 mln shares of its common stock​
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Spero Therapeutics Inc :Spero Therapeutics Inc - ‍Commenced an initial public offering of 5 million shares of its common stock​.Spero Therapeutics Inc - ‍Price range for initial public offering is currently estimated to be between $14.00 and $16.00 per share​.  Full Article

Spero Therapeutics initiates clinical program for SPR994
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Spero Therapeutics Inc :Spero Therapeutics initiates clinical program for oral carbapenem SPR994.Spero Therapeutics - plans for rapid development approach with SPR994 that supports initiation of single pivotal phase 3 trial in second half of 2018​.  Full Article

BRIEF-‍GlaxoSmithKline reports 13.3 percent stake in Spero Therapeutics

* ‍GlaxoSmithKline PLC reports a 13.3 percent stake in Spero Therapeutics Inc as of November 6 - SEC filing​ Source text: (http://bit.ly/2infUEI) Further company coverage: